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ABSTRACT 
Different neurodegenerative diseases have overlapping symptomatology and 
pathology and have thus become a challenge to modern medicine to achieve a 
correct diagnosis. The aim of the thesis was to evaluate the use of 
neurofilaments as biomarkers of neuronal damage by testing their ability to 
discriminate between different neurodegenerative diseases as well as assessing 
whether higher neurofilments predict a poorer clinical outcome in ischemic 
stroke. 
For these purposes, we developed two new Enzyme-Linked ImmunoSorbent 
Assays (ELISAs) for the quantification of neurofilament light (NFL) and 
phosphorylated neurofilament heavy (pNFH) in cerebrospinal fluid (CSF). 
The new NFL and pNFH ELISAs presented good analytical performance and 
both NFL and pNFH concentrations were valid across different analytical 
approaches. CSF-NFL concentrations were significantly higher in 
inflammatory demyelinating diseases and Alzheimer’s disease when compared 
to Parkinson’s disease or controls. In ischemic stroke, both CSF and blood 
NFL and pNFH reflected the temporal dynamics of post ischemic damage of 
axons. Finally, both CSF-NFL and CSF-pNFH were increased in amyotrophic 
lateral sclerosis (ALS) compared to other neurological conditions mimicking 
ALS and controls. 
Both NFL and pNFH proved to be sensitive and reliable biomarkers of 
neuronal damage. These findings support the use of neurofilaments as disease 
intensity markers and suggest that both NFL and pNFH can be useful 
 laboratory tests in the diagnostic work-up of patients with suspected 
neurodegenerative diseases. 
Keywords: neurofilaments, biomarker, neurodegenerative diseases, stroke, 
cerebrospinal fluid, blood. 
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 SAMMANFATTNING PÅ SVENSKA 
Neurodegenerativa sjukdomar har blivit en stor utmaning inom modern 
medicinsk forskning och diagnostik på grund av överlappande 
patofysiologiska mekanismer. Målet för denna avhandling var att utvärdera 
neurofilamentproteiner som potentiella biomarkörer för nervcellsskador. Detta 
genom att kartlägga deras förmåga att skilja olika sjukdomar åt samt identifiera 
patienter med större skador och allvarligare sjukdomsförlopp. 
För att utforska detta utvecklades två nya analysmetoder för att kvantifiera 
neurofilamentproteiner i ryggvätska, baserade på Enzymkopplad 
Immunoadsorberande Analys (ELISA). En för att kvantifiera neurofilament 
light (NFL) och en för att kvantifiera fosforylerat neurofilament heavy 
(pNFH). 
Dessa nya metoder uppvisade god analytisk styrka och mätresultaten var 
konsistenta samt reproducerbara med andra analysmetoder. Koncentrationen 
av NFL i ryggvätska var signifikant högre i de-myeliniserande sjukdomar och 
Alzheimers sjukdom i jämförelse med Parkinsons sjukdom och friska 
kontroller. Både NFL och pNFH återspeglade tidsförloppet av post-ischemisk 
celldöd efter stroke. Båda uppvisade också högre nivåer vid amyotrofisk 
lateralskleros (ALS) i jämförelse med ALS-liknande tillstånd och friska 
kontroller. 
Både NFL och pNFH visade sig vara både känsliga och pålitliga biomarkörer 
för nervcellsskador, vilket stödjer deras användning som  biomarkörer både 
inom diagnostik av neurodegenerativa sjukdomar och för värdering av 
sjukdomsaktivitet. 
Nyckelord: neurofilament, biomarkör, neurodegenerativ sjukdom, stroke, 
ryggvätska, blod. 
 
 
 
 
 RESUMEN EN CASTELLANO 
El hecho que distintas enfermedades neurodegenerativas tienen una 
sintomatología y patología similar y/o común hace que su correcto diagnóstico 
se haya convertido en un gran reto para la medicina moderna. El objetivo de 
esta tesis doctoral fue evaluar el potencial de los neurofilamentos como 
biomarcadores de daño neuronal, valorar su capacidad para discriminar entre 
distintas enfermedades neurodegenerativas, así como examinar si unos 
mayores niveles de neurofilamento predicen un peor pronóstico en el ictus 
isquémico. 
Con este objetivo, se desarrollaron dos nuevos ensayos “Enzyme-Linked 
ImmunoSorbent Assays” (ELISAs) para la cuantificación del neurofilamento 
ligero (NFL) y del neurofilamento pesado fosforilado (pNFH). 
Los nuevos ELISAs para NFL y pNFH presentaron un buen perfil analítico y 
las concentraciones de NFL y pNFH fueron parecidas a las halladas usando 
otras metodologías analíticas. Las concentraciones de NFL en el líquido 
cefalorraquídeo fueron significantemente más elevadas en pacientes con 
enfermedades inflamatorias desmielinizantes y enfermedad de Alzheimer que 
en pacientes con enfermedad de Parkinson o controles. En el ictus isquémico, 
tanto NFL como pNFH en el líquido cefalorraquídeo y en sangre reflejaban la 
dinámica temporal de degeneración axonal post-isquémica. Finalmente, NFL 
y pNFH en el líquido cefalorraquídeo estaban más elevados en pacientes con 
esclerosis lateral amiotrófica (ELA) que en controles o pacientes con síntomas 
similares a los de la ELA. 
Tanto NFL como pNFH han demostrado ser biomarcadores sensibles y fiables 
de daño neuronal. Estos resultados apoyan la utilización de los neurofilamentos 
como marcadores de la intensidad de la enfermedad y concluyen que tanto NFL 
cómo pNFH pueden ser herramientas útiles en el diagnóstico de las 
enfermedades neurodegenerativas.  
 RESUM EN CATALÀ 
El fet que diferents malalties neurodegeneratives tinguin una simptomatologia 
i patologia similar i/o comuna fa que la seva correcte diagnosi hagi esdevingut 
tot un repte per a la medicina moderna. L’objectiu d’aquesta tesi doctoral ha 
sigut avaluar el potencial dels neurofilaments com a biomarcadors de dany 
neuronal, valorar la seva capacitat per discriminar entre diferents malalties 
neurodegeneratives, així com examinar si uns majors nivells de neurofilament 
prediuen una pitjor prognosi en un ictus isquèmic.  
Per aquest motiu, vàrem desenvolupar dos nous assajos “Enzyme-Linked 
ImmunoSorbent Assays” (ELISAs) per a la quantificació del neurofilament 
lleuger (NFL) i del neurofilament pesat fosforilat (pNFH). 
Els nous ELISAs per a NFL i pNFH presentaren un bon perfil analític i les 
concentracions de NFL and pNFH foren similar a aquelles trobades usant 
diferents mètodes analítics. La concentració de NFL al líquid cefaloraquidi va 
ser significadament més elevada en pacients amb malalties inflamatòries 
desmielinitzants i amb malaltia d’Alzheimer que en pacients amb malaltia de 
Parkinson o controls. En els ictus isquèmics, tant NFL com pNFH mesurats en 
el líquid cefaloraquidi o a la sang reflectiren la dinàmica temporal de la 
degeneració axonal post-isquèmica . Finalment, NFL i pNFH en el líquid 
cefaloraquidi estaven més elevats en pacients amb esclerosis lateral 
amiotròfica (ELA) que en controls o pacients que tenen símptomes similars a 
la ELA. 
Tant NFL com pNFH han demostrat ser biomarcadors sensibles i fiables de 
dany neuronal. Aquests resultats recolzen la utilització dels neurofilaments 
com a marcadors de la intensitat de la malaltia i conclouen que ambdós NFL i 
pNFH poden ser eines útils en la diagnosi de malalties neurodegeneratives. 
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ABBREVIATIONS 
AD Alzheimer's disease 
AD-dem Alzheimer's disease dementia 
ALS Amyotrophic lateral sclerosis 
ALS-FTD Amyotrophic lateral sclerosis and Frontotemporal Dementia 
APS Atypical parkinsonian syndrome 
ASPECTS Alberta stroke program early computed tomography score. 
ASPECTS ranges 0-10, the higher the score the better the 
prognosis 
AUC Area under the curve 
BI Barthel index. BI ranges 0-100, the higher the score the better 
the prognosis 
CBD Corticobasal degeneration 
CIS Clinically isolated syndrome 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CT Computed tomography 
ECF Extracellular fluid 
EDSS Expanded disability status scale. EDSS ranges 0-10 and the 
lower the score the better the patient status 
ELISA Enzyme-Linked ImmunoSorbent Assay 
FET The FET protein family includes Fused in sarcoma (FUS), 
Ewing’s sarcoma (EWS), and TATA-binding protein-associated 
factor 15 (TAF15). 
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FTD Frontotemporal dementia 
FTLD Frontotemporal lobar degeneration 
GFAp Glial fibrillary acidic protein 
H&Y Hoehn & Yahr scale. H&Y ranges 0-5, the lower the score the 
less symptoms 
HRE Hexanucleotide repeat expansion 
HS Haemorrhagic stroke 
IDD Inflammatory demyelinating disease 
INA Alpha-internexin 
IQR Interquartile range 
IS Ischemic stroke 
KSP Lysine-serine-proline 
LLOQ Lower limit of quantification 
LOD Limit of detection 
LP Lumbar puncture 
LVO Large vessel occlusion 
MCI Mild cognitive impairment 
MCI-AD Mild cognitive impairment with impairment in episodic 
memory and with evidence of a progressive decline in 
cognitive performance over time 
MMSE Mini-Mental State Examination. MMSE ranges 0-30, the higher 
the score the better the cognitive function 
MND Motor neuron disease 
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MRI Magnetic resonance imaging 
mRS Modified ranking scale. mRS ranges 0-6, the higher the score 
the worse outcome. 6 = death 
MS Multiple sclerosis 
MSA Multiple system atrophy 
mTICI Modified thrombolysis in cerebral ischemia. mTICI ranges 0-3, 
the higher the score the better the recanalization 
NFH Neurofilament heavy 
NFL Neurofilament light 
NFs Neurofilament proteins 
NIHSS National Institute of Health Stroke Scale. NIHSS ranges 0-42, 
the higher the score the worse the stroke severity 
NSE Neuron-specific enolase 
OND Other neurodegenerative disease 
PD Parkinson's disease 
PET Positron-emitted topography 
PLPH Post-lumbar puncture headache 
pNFH Phosphorylated neurofilament heavy 
PPMS Primary progressive multiple sclerosis 
PSP Progressive supranuclear palsy 
ROC Receiver operating characteristic 
RRMS Relapsing-remitting multiple sclerosis 
Simoa Single molecule array 
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SOD1 Superoxide dismutase 1 
SPMS Secondary progressive multiple sclerosis 
SSI Scandinavian Stroke Scale Index. SSI ranges 2-56, the higher 
the score the better the prognosis 
TBI Traumatic brain injury 
TDP Transactive response DNA-binding protein 
tPA Tissue plasminogen activator 
t-tau Total tau 
ULF Unit-length-filament 
UPDRS III Unified Parkinson’s Disease Rating Scale, part III. UPDRS III 
ranges 0-120, the lower the score the less motor symptoms 
VAPB Vesicle-associated membrane protein B 
VaD Vascular dementia 
WB Western blot 
WML White matter lesion 
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1  INTRODUCTION 
The common denominator for all neurodegenerative diseases and acute brain 
injuries is the damage and loss of neurons; it is this phenomenon that gives rise 
to symptoms and loss of cognitive and motor functions [1]. Damaged neurons 
release their cytoplasm contents such as different proteins and molecules into 
the extracellular fluid, from where they can diffuse into adjacent body fluids 
such as cerebrospinal fluid (CSF) and blood. Due to this phenomenon, samples 
of serum, plasma or CSF can be used to measure changes in the levels of these 
proteins [2]. This allows the usage of protein concentrations in biofluids as 
biomarkers that reflect the current state of the brain and estimate the degree of 
neuronal damage [3, 4] (figure 1). 
 
  
CSF 
Blood 
ECF 
neurofilaments 
Figure 1. Protein release into extracellular fluid after neuronal damage.  
Schematic description of the release of the neurofilaments into the body fluids 
after the axon has been damaged. ECF= extracellular fluid, 
CSF=cerebrospinal fluid. 
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1.1 BIOMARKERS 
According to the definition provided by The Biomarkers Definitions Working 
Group (2001) a biological marker (biomarker) is described as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” [5]. The desired properties of a biomarker are that: 
 The biomarker is strongly associated with the disease and 
absent in healthy individuals and other diseases. 
 It captures a biological important aspect of the disease. 
 The concentration of the biomarker reflects the severity of 
the disease and can predict the prognosis. 
 The effect of a therapy is reflected in the change of the 
biomarker concentration [6]. 
A biomarker can have one or more applications including: 
 Use as a diagnostic tool for the identification of patients with 
a disease or abnormal condition. 
 Use as a tool for staging or classifying the extent of the 
disease or condition. 
 Use as an indicator of disease progression and prognosis. 
 Use as a monitor of the response to a treatment [5].  
In humans, biomarkers can be measured in tissue or body fluids such as blood, 
cerebrospinal fluid, saliva or urine. 
For a biomarker to be used in the clinic, it needs to first be validated and 
qualified. The validation process assesses the biomarker’s characteristics, such 
as sensitivity, specificity and determines the conditions under which the results 
are reproducible. Qualification is a process where evidence linking the 
biomarker with a biological process and/or a clinical end point is acquired 
through clinical studies [7].  
 
1.2 CEREBROSPINAL FLUID 
Cerebrospinal fluid (CSF) is a clear, colourless body fluid produced in the 
choroid plexus of the ventricles situated in the centre of the brain, as well as 
from the brain interstitial fluid. It occupies the ventricular system as well as 
3 
 
surrounds the brain and the spinal cord. CSF has two main functions, first, by 
submerging the brain it provides a cushion against trauma preventing 
mechanical injuries to the brain, and second, it provides a medium to transport 
nutrients and waste products to and from the brain tissue [8]. In normal healthy 
adults, the total volume of CSF is around 150mL. CSF is produced at a rate of 
around 500mL/day, which ensures a constant flow into and around the brain 
and the spinal cord; old CSF is eventually cleared into the blood, ensuring a 
stable environment and assisting in the removal of waste products [9]. Thus, 
by being in close contact with the central nervous system (CNS), CSF provides 
a good reflection of the status of the brain. 
The most common procedure to obtain CSF is through a lumbar puncture (LP) 
between L3/L4 or L4/L5 vertebrae. It is a safe procedure and the only potential 
complication is post-lumbar puncture headache (PLPH). However, the 
incidence of PLPH is very low [10]. As a standardized protocol, 12mL of CSF 
are collected, then centrifuged at 2000g for 10 minutes and finally the 
supernatant is aliquoted and stored at -80°C until further use [11].  
 
1.3 NEUROFILAMENTS 
Visually, the most distinct characteristic of neurons is their extreme 
morphology with long extensions and protrusions, which makes their 
cytoskeleton key for their stability and consequently good cellular function. 
The principal elements of the cytoskeleton are actin filaments (~7nm in 
diameter), intermediate filaments (~10nm in diameter) and microtubules 
(~25nm in diameter). Intermediate filaments have a basic role in cells 
providing mechanical strength and stability, whereas actin filaments and 
microtubules are responsible for cell movement [12]. 
Intermediate filaments can be classified into six  types based on similarities in 
their amino acid sequences (Table 1) [12].  
From all the cytoskeletal proteins, the ones belonging to the Type IV 
intermediate filaments are called neurofilament proteins (NFs) and are the only 
ones expressed specifically in neurons, at the exception of peripherin, a type 
III intermediate filament expressed in the peripheral neurons. Due to their long 
axons, NFs are the key in the extreme neuron morphology maintenance for a 
good cellular function. They share a conserved α-helical rod domain flanked 
by an N-terminus head domain and a variable C-terminus tail domain [13]. 
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The structural neurofilaments are composed of four NFs, including α-
internexin (INA) (66kDa), which is CNS-specific, and the neurofilament triplet 
consisting of NF light (NFL) (68kDa), NF medium (NFM) (150kDa) and NF 
heavy (NFH) (200kDa), identified by their molecular weights (Table 1) [14, 
15]. 
The diversity in NFs is primarily due to the length and sequence of the C-
terminal tail, where NFH exhibits the longest. Its most distinctive feature is the 
presence of numerous lysine-serine-proline (KSP) repeat motifs, varying 
between 8 and 58 repeats, depending on species (figure 2a) [14].  
NFs are synthetized in the cell body and then transported to the axon, where 
they assemble to form the filaments that give structure and stability to the 
neuron [16]. 
Table 1. Intermediate filaments classification. 
Type Protein 
Size 
(kDa) 
Site of expression 
I Acidic keratins 40–60 Epithelial cells 
II 
Neutral or basic 
keratins 
50–70 Epithelial cells 
III 
Vimentin 54 
White blood cells, 
fibroblasts, other cell 
types 
Desmin 53 Muscle cells 
Glial fibrillary acidic 
protein  
51 Glial cells 
Peripherin 57 Peripheral neurons 
IV 
NFL 68 Neurons 
NFM 150 Neurons 
NFH 200 Neurons 
α-Internexin (INA) 66 
Neurons (CNS-
specific) 
V Nuclear lamins 60–75 
Nuclear lamina of all 
cell types 
VI Nestin 200 CNS stem cells  
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The mechanism behind the assembly of the NFs to form filaments follows 
several steps. First INA or NFL aligns with any of the other NFs, through 
association of the conserved rod domains, to form parallel and coiled-coil 
dimers. Then, two dimers line up side by side in an antiparallel manner (head 
to tail) to form tetramers. Thereafter, about eight tetramers will aggregate 
laterally to form a unit-length-filament (ULF) of approximately 55nm in 
length. A longitudinal aggregation of ULFs lead to the formation of immature 
filaments of about 16 nm of diameter. The last step is a radial compaction 
resulting in a close packing of the molecular filaments to form the final 10nm 
neurofilament (figure 2b-c) [17]. This structure is a so called “bottlebrush” 
because NFM and NFH tails form side arms that protrude from the central 
filament core formed by the compaction of all NFs rod domains.  
In vitro experiments have shown that NFL is essential for the formation of 
neurofilaments, since it is the only neurofilament that can homopolymerize, 
meaning that NFM and NFH have to bind to NFL to be able to form filaments 
Figure 2. Type IV intermediate filaments. a) Neurofilament protein 
structures. b) Neurofilament protein assemblies. c) “Bottlebrush” structure 
representation. 
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[18, 19]. In support, in vivo studies have observed that NFs are compulsory 
heteropolymers [20]. Furthermore, it has been reported  that the central α-
helical coiled-coil rod domain is essential for NF assembly into dimers [21], 
whereas the head domain directs the lateral association of the tetramers into 
ULFs and the tail domain guides the axial association of ULFs into immature 
neurofilaments [17, 22].  
Phosphorylation plays an important role in the assembly of the neurofilaments 
and is involved in various other functions. The phosphorylation of the NFL 
head domain controls the heteropolymer formation [20], inducing assembly 
when not phosphorylated, or disassembly when phosphorylated [18, 23]. The 
head domain phosphorylation may occur shortly after NFL synthesis in the cell 
body, suggesting that a premature assembly of NFs is avoided before their 
transport to the axon [24].  
Many roles have been associated to the phosphorylation of the KSP motifs in 
the tails of NFM and NFH. Some examples are; the slowing of the NFs axonal 
transport, the formation of cross-bridges between neurofilaments or 
microtubules and the expansion of the axonal calibre [18]. 
NFM and NFH are found to be heavily phosphorylated after they have been 
transported through the axon suggesting that NFM and NFH tail 
phosphorylation occurs in a gradient manner along the axon, beginning when 
the NFs enter the axon and continuing along it until they reach their final 
destination [25, 26]. Another suggested function of the tail phosphorylation of 
NFM and NFH is to protect them from protease degradation. 
Dephosphorylated NFs are easily degraded by calpain, a protease found in the 
axons [27].  
Tail phosphorylation has also been shown to modulate NFs interactions with 
other cytoskeletal proteins such as microtubules [28]. When NFH tail is 
dephosphorylated it has a high binding affinity to the microtubules, but when 
phosphorylated it causes their dissociation [29].   
Some studies using different NF mouse models (knockout and transgenic 
mice) suggest that the phosphorylation of the NFM and NFH tails only 
contributes in part to the radial growth of big calibre axons [30] and that instead 
it is the subunit composition and the ratio of the NFs that determines axon 
calibre by controlling their number [31].  It has been shown that in the adult 
mouse CNS the stoichiometry of the NFs is 4:2:2:1 being NFL, INA, NFM and 
NFH respectively [32]. 
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1.4 NEURODEGENERATIVE DISEASES 
Neurodegenerative diseases can be defined as diseases that result from a 
progressive impairment in neuronal function and structure, which eventually 
leads to neuronal death. Neurodegenerative diseases include both dementias 
and movement disorders and their presentation depends on the affected area of 
the brain and the employed degenerative mechanism [33]. Common aspects of 
neurodegenerative diseases are the deposition of protein aggregates in the 
nucleus, cytosol and/or extracellular space [34, 35]. 
Some neurodegenerative diseases have a clear genetic component; if inherited, 
the familial form of the neurodegenerative disease in question develops [36].  
In most neurodegenerative diseases, the onset of symptoms does not equate 
with the onset of disease pathology. The symptoms begin after enough neurons 
have been damaged and/or died, and the functions of the affected area cannot 
be maintained, meaning that the onset of the disease pathology occurs earlier 
in time. The time needed for the appearance of symptoms depends on the 
neurodegenerative process and can range from a few months to several years, 
depending on the neurodegenerative disease. This means that the disease may 
be relatively advanced by the time the symptoms are observed [33, 36]. 
Giving an accurate diagnose is quite complicated due to that many 
neurodegenerative diseases share a progressive clinical course of the disease. 
As such, postmortem neuropathologic evaluation is still the gold standard for 
the diagnosis of neurodegenerative diseases [37]. Hence finding diagnostic 
tools to facilitate accurate and earlier diagnosis is much needed.  
 
1.4.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) was first described during the early 20th century by 
Alois Alzheimer in a patient who presented with memory disturbances and 
later develop dementia [38]. Today, AD is classified as a neurodegenerative 
disease clinically characterized by progressive cognitive decline, usually 
starting with an impairment in the ability to form recent memories, and 
progressing into a disruption of executive function, affecting the ability to 
perform daily basic activities [39]. AD is the most common cause of dementia,  
accounting for about 60-80% of all cases [40]. The disease affects over 46 
million people worldwide (2015) with a prevalence of 5 per 100 individuals in 
Europe [41, 42].  
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Neuropathologically, AD is characterised by extracellular depositions of 
amyloid-beta (Aβ) forming large aggregates called plaques, and intraneuronal 
accumulation of hyperphosphorylated microtubule-associated protein tau (p-
tau) forming fibrillary tangles [39, 43, 44]. It has been demonstrated that AD 
has a long pre-clinical phase that is suggested to start decades before the 
earliest clinical symptoms arise [45].  
The diagnosis of AD is traditionally based on clinical history and cognitive 
testing by the clinician, and according to the latest reviewed diagnostic criteria, 
the clinical onset of AD can be divided into three different phases: preclinical, 
mild cognitive impairment (MCI), and AD dementia (AD-dem) [46-49].  
The CSF biomarkers Aβ, total tau (t-tau), and phosphorylated-tau (p-tau), 
which are primarily used in research settings, combined with volumetric 
magnetic resonance imaging (MRI) and positron-emitted topography (PET) 
can help evaluate and monitor the progression of AD pathology as well as 
significantly improve the differentiation of AD from other diseases [50]. These 
biomarkers are used in the revised definitions of all three AD phases for 
different purposes. In the preclinical phase, the biomarkers are used only in 
research for the establishment of AD pathology in study subjects with no or 
very subtle clinical symptoms. In MCI and dementia stages of the disease, the 
biomarkers are used as a complement to the clinical diagnosis to establish the 
underlying pathology [47, 51].  
To date, only symptomatic treatments exist for this disease [43], and treatments 
capable of stopping or at least effectively modifying the course of AD are still 
not available but under extensive research [52, 53]. 
 
1.4.2 PARKINSON’S DISEASE 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder after AD with prevalence estimates ranging from 66 to 12500 per 
100000 individuals in Europe [54].. 
PD symptomatology is characterized by the classical parkinsonian motor 
symptoms, such as bradykinesia, resting tremor, rigid musculature and postural 
imbalance, as well as non-motor features including cognitive impairment, 
sleep disorders, olfactory dysfunction, psychiatric symptoms, autonomic 
dysfunction, pain, and fatigue [55, 56]. 
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Neuropathologically, PD is characterised by the loss of dopaminergic neurons 
in the substantia nigra, as well as aggregation of misfolded alpha-synuclein 
protein in intracellular inclusions within the cell body and processes of neurons 
(Lewy bodies and Lewy neurites, respectively) [55, 57]. 
The diagnosis of PD is based on clinical features and it can only be confirmed 
after autopsy. However, a DaTscan, a dopamine transporter single photon 
emission computerized tomography imaging technique has the potential to 
provide support in diagnosis, especially for those patients who have an unclear 
presentation of parkinsonian motor symptoms [58]. Currently, no biomarkers 
are used in the diagnosis of PD; however, CSF alpha-synuclein has been 
suggested as a potential candidate [59, 60].  
There are no treatments that slow the neurodegenerative process of PD. 
However, therapies to treat motor symptoms of PD, mainly by increasing 
dopamine concentrations or stimulating dopamine receptors, are available and 
should be administered when the symptoms cause disability or discomfort to 
the patient with the aim of improving their quality of life [55, 61]. 
 
1.4.3 FRONTOTEMPORAL DEMENTIA 
Frontotemporal dementia (FTD) is an umbrella term that encompasses a group 
of neurodegenerative diseases characterized by a selective degeneration of the 
frontal and temporal lobes, causing progressive deficits in behaviour, executive 
function and/or language [62]. 
The estimated prevalence of FTD is 15 to 22 per 100000 people and it is the 
second most common dementia in persons under 65 years of age [63] and the 
survival time from diagnosis is around 3 to 4 years [64].  
FTD is clinically diagnosed [65] and can be sub divided into three broad 
molecular subgroups depending on the major constituent of the intracellular 
protein aggregates. These groups are frontotemporal lobar degeneration 
(FTLD) with tau, FTLD with transactive response DNA-binding protein 43 
(TDP-43) and FTLD with FET [66]. The FET protein family includes Fused 
in sarcoma (FUS), Ewing’s sarcoma (EWS), and TATA-binding protein-
associated factor 15 (TAF15). As of today, there are no specific biomarkers for 
FTD, however, the core biomarkers for AD (Aβ, t-tau and p-tau) can be used 
to differentiate AD patients from FTD patients [67, 68]. 
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There are currently no approved disease-modifying treatments for FTD. 
However, there are medication strategies for the management of behavioural 
symptoms [69]. 
 
1.4.4 AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative motor neuron 
disease (MND) characterized by progressive loss of upper and lower motor 
neurons [70]. ALS remains a relatively rare disorder with a prevalence of five 
patients per 100000 people in Europe [71].  
In most patients, ALS starts with a spinal onset with asymmetric, painless 
weakness in a limb. Weakness, muscle atrophy and fasciculations are signs of 
lower motor neuron damage, whereas hyperreflexia and hypertonia indicate 
upper motor neuron involvement [72]. In the other cases, the weakness starts 
in the bulbar muscles (bulbar onset), which results in symptoms such as 
dysarthria, dysphagia and tongue fasciculations [72]. In the majority of cases, 
the cause of ALS is unknown, but in about 15% a genetic cause can be found 
[72]. More than half of cases of familial ALS present mutations in super oxide 
dismutase 1 (SOD1), TDP-43, FUS and C9orf72 genes [72]. 
Patients typically survive 2 to 5 years after symptom onset and only 5–10% 
survive beyond 10 years [73, 74]. There is no cure for the disease and the cause 
of death is most commonly due to respiratory failure [73]. However, two 
different treatments to slow the disease progression and increase the survival 
of patients are available [75].  
An ALS diagnosis is made on the basis of clinical evaluation of motor 
symptoms and the ruling out of differential diagnoses occasionally 
masquerading as ALS. Due to the lack of definitive diagnostic tests for ALS 
and the occasionally lengthy investigations, most patients will have to wait up 
to a year for a diagnosis [76].  
A biochemical diagnostic biomarker could be of assistance to physicians to 
increase the diagnostic certainty, as well as to accelerate the diagnostic work-
up, especially during the early stages of the disease when it may be difficult to 
differentiate ALS from common mimics, such as Kennedy disease, motor 
neuropathies, myopathies and myelopathies [77, 78]. 
Approximately 15% of ALS patients show cognitive and/or behavioral 
dysfunction and TDP-43 positive inclusions in cortical neurons as in FTD [79]. 
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While 15% of FTD patients present motor neuron symptoms as in ALS. 
Patients with clinical evidence for both disorders have ALS-FTD [80]. 
 
1.4.5 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease that 
damages the CNS. The concept that the immune system plays a critical role in 
the pathogenesis of MS is indisputable [81, 82]. However, axonal 
demyelination and consequent neuronal degeneration is accepted as the major 
cause of permanent disability in MS patients [83, 84]. Therefore, MS is 
described as a primary inflammatory demyelinating disease with secondary 
axonal and neuronal degeneration, hence, the inclusion of MS under 
neurodegenerative diseases in this thesis. 
MS affects approximately 2.3 million people worldwide with a prevalence of 
108 cases per 100000 in Europe [85]. It causes a heterogeneous array of 
symptoms and signs, such as tremors, clumsiness and poor balance, vertigo, 
impaired swallowing, stiffness, painful spasms, temperature sensitivity and 
pain [86]. 
MS often starts with a course of recurrent and reversible neurological deficits. 
This phase is termed relapsing-remitting MS (RRMS). With time, the majority 
of RRMS patients enter a second disease phase, termed  secondary progressive 
MS (SPMS), and characterised by continuous, irreversible neurological 
decline unrelated to relapses. The transition from RRMS to SPMS can only be 
delayed by treatment but not prevented [87]. In some patients, the course of 
the disease is progressive from the very first symptoms, which is called 
primary progressive MS (PPMS) [88]. The clinically isolated syndrome (CIS) 
is characterised by an episode comparable to an MS relapse but the patient does 
not fulfil the criteria to be classified as MS. A patient with CIS may convert to 
RRMS if, for example, new relapses occur [89]. 
The diagnosis of MS is based on typical clinical symptoms with support of 
MRI and laboratory tests such as oligoclonal bands in CSF and not in blood 
[89]. 
The treatment of MS can be divided into three categories: symptomatic 
treatment, relapse treatment and disease-modifying treatment. Symptomatic 
treatments are not specifically approved for MS only and are used to improve 
several of the patient symptoms such as pain, balance impairment, spasticity, 
depression and weakness. While relapse treatments improve symptoms and 
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short-term disability after an acute relapse, disease-modifying treatments can 
mitigate the disease course and improve prognosis by inhibiting inflammation 
[90-93].  
 
1.4.6 NEUROFILAMENTS IN NEURODEGENERATIVE 
DISEASES 
Since the first developed NFL assay with a high enough sensitivity to analyse 
CSF [94], high CSF-NFL concentrations have consistently been found in a 
variety of neuroinflammatory and neurodegenerative diseases. 
CSF-NFL concentration has been shown to be increased in AD compared with 
healthy controls [95], and NFL levels correlate with disease progression [96]. 
NFL concentration has also been reported to be increased in serum and plasma 
from AD patients compared with controls, and these levels correlate with those 
in CSF [97, 98].  
CSF-NFL has also been shown to be a possible useful biomarker for the 
differentiation of PD from atypical parkinsonian syndromes (APS) such 
as multiple system atrophy (MSA), progressive supranuclear palsy 
(PSP) and corticobasal degeneration (CBD). NFL concentration is 
reported to be higher in APS than PD and healthy controls [99-102].  
Elevated NFL concentrations in CSF have been reported also for other types 
of dementias, such as frontotemporal dementia and vascular dementia (VaD), 
where NFL levels are found to be even higher than those found in AD patients 
[95, 103].  
Some neurodegenerative diseases share part of their symptomatology and 
neuropathology making it difficult to differentiate between them, as in the 
overlap between FTD and ALS [80]. NFL could become a useful tool since it 
has been shown that both serum and CSF-NFL concentrations are higher in 
ALS than in FTD as well as than in AD and healthy controls [98, 104-108]. 
Furthermore, CSF-NFL has been found to be significantly higher in patients 
with FTD-ALS than in patients with FTD without ALS [109]. 
Interestingly, phosphorylated neurofilament heavy (pNFH) also showed 
capability to differentiate ALS patients from controls [110, 111]. In addition, 
concentrations of NFL and pNFH in CSF have been shown to correlate with 
survival length in ALS [106, 108, 112], and CSF-NFL concentration predicted 
the conversion from bulbar/spinal to generalised ALS [113]. ALS mutation 
carriers with ALS symptoms had higher NFL in CSF and serum than those 
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without ALS symptoms [114], showing that elevated NFL levels are linked to 
the symptomatic disease phase, and that it probably is an indicator of an 
ongoing neurodegenerative process, suggesting the use of NFL as a 
progression marker. However, it is suggested that pNFH is a better diagnostic 
marker because it can better differentiate ALS from other diseases mimicking 
ALS symptoms [115].  
NFL is one of the most studied biomarkers in MS. It is found to be increased 
in both CSF and blood in CIS, RRMS, PRMS and SPMS, especially after 
relapse [116-118]. CSF-NFL at disease onset may be able to predict the disease 
severity and the conversion from CIS to clinically diagnosed MS [119-121]. 
NFL concentration in both CSF and blood is reduced after treatment [122-126]. 
CSF-NFH correlated to relapses and disability in MS patients [127]. However, 
NFL has been suggested to be a better biomarker than NFH to monitor 
treatment effects [128]. 
In addition, NFL in CSF and serum is also a biomarker reflecting induced 
neuronal damage in a mouse model, where NFL is increased after induction of 
neurodegeneration but does not increase after the induction is stopped, 
suggesting that NFL mirrors the ongoing neurodegeneration and neuronal loss 
[129]. The levels of NFL also correlated with the extent of neuronal damage 
(assessed through immunostaining), suggesting that NFL could be used as a 
dynamic marker of neurodegeneration [129]. This is a confirmation that NFL 
is also increased in a pre-clinical model where neurodegeneration can be 
induced, concluding that NFL is a translational biomarker that can be used 
when developing therapeutics to monitor treatment effects. 
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1.5 ACUTE BRAIN INJURIES 
Acute brain injuries are medical emergencies that differ from 
neurodegenerative diseases in that the death of neurons is acute rather than 
progressive. In these events, the neuronal damage is caused by a sudden insult 
to the brain. Stroke, traumatic brain injury (TBI), subarachnoid haemorrhage 
and hypoxic brain injury following cardiac arrest are examples of acute events. 
 
1.5.1 ISCHEMIC STROKE 
A stroke can cause long-term disability, lasting brain damage or death, making 
it a major public health problem [130]. Stroke occurs when the blood supply 
to a part of the brain is blocked (ischemic stroke; IS) or when a blood vessel in 
the brain bursts (haemorrhagic stroke; HS) (figure 3.). In western countries, IS 
accounts for 87% of total stroke type while the rest 13% is subjected to HS 
[131].  
Common signs of stroke are face dropping, arm weakness and speech difficulty 
[132]. Currently, non-contrast computed tomography (CT) imaging of the 
brain is most routinely used for confirming the diagnosis of stroke and 
distinguishing IS from HS. No blood biomarkers have been validated for 
diagnosis and differentiation purposes [131]. 
During IS, the brain tissue of the affected area is deprived of oxygen, usually 
resulting in a fatally injured core and a salvageable surrounding area called the 
penumbra. The core, where the blood clot occurs, can receive about 10-25% 
of the normal blood flow, leading to infarction and tissue necrosis. The 
penumbra, which is the ischemic tissue surrounding the core, can receive blood 
from collateral circulation, delaying completion of the infarct and therefore the 
neurons in the penumbra are salvageable if the area is re-perfused in time [133]. 
Treatment of IS relies on the possibility to administer thrombolytic agents, 
such as tissue plasminogen activator (tPA), within a narrow time window of 3-
4.5 hours after symptom onset [134]. After the publication of five crucial 
clinical trials [135-139], endovascular thrombectomy has been accepted as the 
standard care for patients with large vessel occlusion (LVO) in the anterior 
circulation [140]. 
The affected tissue releases neuronal and glial proteins into the CSF and blood. 
Potentially, these proteins can be used as biomarkers to determine the degree 
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of damage, as indicators of disease prognosis, as well as to predict and monitor 
the response to an intervention [5, 141, 142]. 
 
1.5.2 NEUROFILAMENTS IN ACUTE BRAIN 
INJURIES 
NFL has been assessed in mild traumatic brain injuries in contact sports 
such as boxing, where serum-NFL was able to differentiate boxers with 
severe concussion from boxers with milder impacts as well as identify 
those boxers who would recover faster from post-concussion symptoms 
[143]. Similarly, NFL was increased in CSF after acute ischemic stroke 
Figure 3. Schematic representation of haemorrhagic and ischemic stroke.  
During haemorrhagic stroke a vessel in the brain bursts causing bleeding (red 
area) inside the brain, then the brain tissue is deprived of oxygen and nutrients 
(grey area) and begins to die; if the bleeding is severe pressure can build up 
inside the skull and cause tissue damage in other areas. During ischemic 
stroke, a vessel in the brain is clogged, and then the brain tissue is deprived of 
oxygen and nutrients (grey area) and begins to die. 
 
 
Haemorrhagic 
Stroke 
Ischemic 
Stroke 
Grey matter 
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compared to controls and it was significantly associated to white matter 
lesions (WML) [141]. In severe brain trauma, serum-NFL concentration 
after time of admission in the hospital was able to differentiate patients 
with favourable outcome from those with poor outcome and survivors 
from non-survivors [144]. 
To date, NFM has only been reported in one clinical study, where its 
concentration was measured in the CSF of patients with HS, IS and 
controls and serum of patients with TBI and controls. The results 
showed that NFM was elevated in the HS group compared with IS and 
controls, and that there was no difference between IS and controls [145]. 
In addition, NFM was significantly higher in TBI than in controls [145]. 
However, NFH levels in CSF and serum of stroke patients have shown 
conflicting results. Petzold et al. showed no differences in CSF and 
serum NFH levels comparing IS and controls [142], while Sellner et al. 
reported higher levels of serum-NFH in stroke patients than in controls 
[146]. The contrasting results between the two studies can possibly be 
explained by the fact that the Sellner stroke cohort included both IS and 
HS and that there may be differences in how NFH behaves in these two 
conditions, resembling NFM [145]. 
Serum-pNFH has also been reported in TBI and IS studies. In IS, 
increasing concentrations of pNFH from day 1 to day 8 and 3-6 weeks 
after arrival in the hospital were reported [147]. Serum levels of pNFH 
at 3 weeks after IS correlated with infarct volume and the final outcome 
evaluated 6 months after hospital discharge [147]. In TBI, serum-pNFH 
levels at 72h after hospital arrival were significantly higher than at 24h 
after arrival. Serum-pNFH at 24 hours after injury was shown to be a 
good predictor of fatal outcome in patients with TBI [148]. 
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1.6 OTHER BIOMARKERS STUDIED IN THIS 
THESIS 
1.6.1 TAU 
Tau is a microtubule-associated protein, mainly located in unmyelinated axons 
[149]. Its main function is to stabilize microtubules. By regulating the 
microtubule assembly, it allows the reorganisation of the cytoskeleton [150]. 
It has also been reported that tau regulates axonal transport by different 
mechanisms [151]. Tau has also been detected in dendrites; however, its 
function there is still unclear [152]. Tau is an established biomarker in 
neurodegenerative diseases, such as Creutzfeldt-Jakob disease and AD [153, 
154], and is believed to reflect ongoing axonal degeneration. Levels of tau have 
also been found to be increased in both blood and CSF after stroke [141, 154]. 
Immunohistochemistry staining for tau has been shown to be decreased in the 
infarcted region of a rodent brain 24h after experimental large vessel occlusion 
when compared to controls, suggesting that tau is released or degraded during 
ischemia [155]. 
 
1.6.2 GLIAL FIBRILLARY ACIDIC PROTEIN 
Glial fibrillary acidic protein (GFAp) is the main intermediate filament protein 
in astrocytes [156]. GFAp is a vital component of the astroglial cytoskeleton 
providing mechanical strength to the cell [157, 158]. It also has a number of 
other functions, such as playing a role in suppressing neuronal proliferation in 
the mature brain [159], forming a physical barrier to isolate damaged tissue 
[160, 161], as well as regulating the blood flow following ischemia [162]. 
GFAp immunoreactivity has been shown to be decreased in infarcted regions 
of post-mortem human brain [163]. CSF levels of GFAp are increased in 
neurodegenerative diseases, such as AD and multiple sclerosis [164, 165], as 
well as after stroke [166, 167] and TBI [168]. 
 
1.6.3 NEURON-SPECIFIC ENOLASE 
Neuron-specific enolase (NSE) is an isozyme of the glycolytic enzyme enolase 
[169]. Human NSE is a major brain protein that constitutes between 0.4% and 
2.2% of the total soluble protein of brain, depending on the region [170] 
making it a plausible marker of neurons [171], but NSE is also expressed in 
neuroendocrine tissue, erythrocytes and platelets [172, 173]. NSE has been 
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proposed as a biomarker for neuronal damage in TBI and stroke, and as a tool 
in cancer diagnostics [174-176]. Blood NSE dynamics after stroke are 
controversial; while some studies show an increase of NSE [177], others report 
no significant changes over time [178, 179]. 
 
1.6.4 S100B 
S100B is one of the 20 proteins that belong to the S100 protein family; they 
represent the largest subgroup of Ca2+-binding proteins characterized by the 
EF-hand structural motif [180]. In the nervous system, S100B is mainly found 
in astrocytes but also in other cell types and its presence is not restricted to 
neuronal tissue, as it is expressed, e.g., in adipose tissue [181, 182]. S100B has 
been reported to increase in CSF and blood after stroke [167], but also in other 
acute disorders, such as traumatic brain injury [183]. 
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2 AIM 
2.1 GENERAL AIM 
The overall aim of this thesis is to investigate and evaluate the use of 
neurofilaments as biomarkers in different situations involving neuronal 
damage. 
2.2 SPECIFIC AIMS OF EACH PAPER 
Paper I: To confirm the diagnostic utility of NFL using a newly developed 
NFL ELISA based on in-house-produced antibodies. Its performance was 
evaluated in different neurological disorders.  
Paper II: To examine the temporal pattern of NFL and pNFH concentrations 
in serum and CSF after acute ischemic stroke. To test this aim, a new pNFH 
ELISA was developed. 
Paper III: To compare the analytical sensitivity and reliability of three novel 
analytical approaches for the quantification pNFH in both CSF and serum in 
samples of ALS, FTD and control subjects. 
Paper IV: To investigate the progression of nervous tissue damage and their 
relationship to outcome after endovascular treatment of acute ischemic stroke 
by the parallel analyses of tau, NFL, NSE, GFAp and S100B in blood, as well 
as to determine their possible use as prognostic biomarkers. 
Paper V: To test the hypothesis that CSF NFL and pNFH can differentiate 
ALS patients from patients with ALS-like symptoms who eventually received 
a different diagnosis. Examine if the biomarkers are correlated to survival and 
if the mutation type of the mutation carriers has an influence on the biomarker 
levels. 
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3 MATERIAL AND METHODS 
3.1 PARTICIPANTS SAMPLES 
All participants in the studies gave their informed consent and sample 
collection was performed according to the ethical permissions approved by the 
corresponding ethical committees. More detailed information about the 
participants can be found in the respective papers. 
For method development, de-identified CSF and serum samples from the 
Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital 
were used. 
 
3.2 IMMUNOASSAYS 
There are different types of immunoassays but what all of them have in 
common is the use of antibodies to detect and quantify the analyte of interest. 
 
3.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY 
An enzyme-linked immunosorbent assay (ELISA) is a type of immunoassay 
that uses an enzymatic reaction to detect and quantify an analyte of interest. In 
general, the analyte (antigen) is immobilized on a surface and then detected 
with an antibody that is linked to an enzyme. To detect the immunocomplex, 
the conjugated enzyme activity is assessed by the incubation with a substrate 
to produce a product that can be measured through a change in colour or 
through light emission. The amount of the product is directly proportional to 
the concentration of the analyte of interest in the sample and can be quantified 
when compared to the assay signal generated from a set of standard samples 
with known concentrations of the target analyte (a standard curve).  
There are different types of ELISAs depending on how the antigen is 
immobilized to the assay plate and detected. The analyte can be either directly 
bound to the assay plate or bound through a capture antibody and then, directly 
detected with another antibody (primary antibody) linked to the detection 
enzyme or indirectly detected when the enzyme is linked to a secondary 
antibody that binds the primary detection antibody. Commonly, the term direct 
ELISA is used when the analyte is directly bound to the plate, irrespectively if 
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it is directly or indirectly detected, and the term sandwich ELISA is used when 
the analyte is immobilized to the plate with a capture antibody, irrespective of 
a direct or indirect detection (figure 4). The most common ELISA assay format 
is the sandwich assay since it is more sensitive, specific and robust.  
In paper I, II, IV and V a sandwich ELISA was used to detect NFL with a 
colorimetric substrate whereas the sandwich ELISA used to measure pNFH 
used a chemiluminiscent substrate. 
In paper I, a direct ELISA was used to screen the cell media for NFL 
antibodies. 
Figure 4. Schematic representation of different types of ELISA. 
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3.2.2 SINGLE MOLECULE ARRAY 
Single molecule array (Simoa) is the newest type of immunoassays and is 
somewhat similar to a sandwich ELISA with the difference that it uses 
magnetic beads coated with the capture antibody and a fluorescent detection 
enzyme with a compartmentalized detection reaction in microwells into which 
only one magnetic bead per well can fit.  
The general procedure for a Simoa is as follows: after the binding of the analyte 
to the antibody-coated beads, nonspecific proteins are washed away and the 
beads are then incubated with a biotinylated detector antibody. The incubation 
with detector antibodies is followed by another incubation with β-
galactosidase-labelled streptavidin (SBG). Beads are then individually placed 
in wells containing substrate, sealed in with oil and finally imaged. The 
concentration of the analyte is determined by counting the wells that contain a 
bead compared to the total amount of wells containing a bead that emits a 
fluorescent signal (digital signal). If the concentration of the analyte is too 
strong or takes too long, the samples will be detected using an analogue 
technique wherein the total amount of fluorescence emitted by all wells is 
detected [184].  
The Simoa is capable of improving the sensitivity of a normal ELISA ~100-
1000 times depending on the analyte [184]. 
In paper II, Simoa was used to measure NFL concentration in blood.  
In paper III, two different Simoa methods were used to measure pNFH 
concentrations in CSF and blood.  
In paper IV, Simoa was used to measure NFL, tau and GFAp concentrations 
in blood. 
 
3.3 IMMUNOPRECIPITATION 
Immunoprecipitation (IP) is an antibody-based enrichment technique, where 
the principle is to couple a specific antibody capable to capture the protein of 
interest onto magnetic beads. The coupled beads are then incubated in the 
sample where the antibodies will bind the protein of interest and form a bead-
antibody-protein complex that can be separated from the rest of the sample 
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proteins by using a magnet. In the end, there is an elution step isolating your 
protein of interest. 
In paper I, IP was used to characterize the in-house produced NFL antibodies. 
 
3.4 WESTERN BLOT 
Western blot (WB) is a technique that can be used to both characterize 
antibodies and to detect specific proteins in a sample. Its principal consists of 
three steps. First, the sample proteins are separated based on size in an 
electrophoresis gel. Second, the proteins are transferred onto a membrane, 
where they are fixed. Third, the protein of interest is detected with an antibody. 
If you would stain the gel after the electrophoresis, using a general protein 
stain, such as silver or Coomassie, you would see all the protein bands that 
your sample contained, whereas using WB you only see the bands 
corresponding to the protein your antibody has bound to. To characterize 
antibodies, you check for cross-reactivity by including other similar proteins 
(in our case the other NFs) and evaluate if the antibody can bind to them. 
Fragments of the target protein can also be included to define where on the 
protein the antibody binds. 
In paper I, WB was used to characterize the in-house produced NFL antibodies. 
 
3.5 STATISTICS 
In paper I, a likelihood ratio test based on generalized linear models was used 
to test if the distribution of demographics and clinical features differed between 
each diagnostic group subcategories. NFL was log-transformed to reach 
normality and an analysis of covariance (ANCOVA) was used to test if CSF 
NFL log values would differ between the diagnostic groups. The diagnostic 
accuracy of NFL was assessed by the receiver operating characteristic (ROC) 
curve at the point that maximized the Youden index (sensitivity + specificity-
1). The statistical analyses were performed using R software, version 3.3.1. All 
tests were two-sided and significance was set at p≤0.05. 
In paper II, a Mann-Whitney test was used for comparisons between controls 
and the other time points. Mixed effect model analyses were performed on each 
biomarker repeated measurements where subjects were included as random 
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factors and age and gender as covariates. Correlations between groups were 
analysed with Spearman’s non-parametric test. All tests were two-sided and 
significance was set at p≤0.05. Statistical analyses were performed using SPSS 
software, version 23.0. Samples below the limit of detection (LOD) were 
included in the statistical analysis as half the LOD (0.033ng/mL). 
In paper III, Spearman’s non-parametric test was used to analyse correlations 
of pNfH concentrations between and within analytical approaches. Mann-
Whitney tests were used to determine if there are differences in pNFH 
concentrations between the different diagnosis groups. All tests were two-
sided and significance was set at p≤0.05. Statistical analyses were performed 
using SPSS software, version 23.0. 
In paper IV, the change of the biomarker concentration over time was analysed 
with mixed effect models. Subjects were included as random factors and age, 
gender, NIHSS at admission, type of anaesthesia, the use of intravenous 
thrombolysis and the use or no use of vasoactive drug during the embolectomy 
procedure as covariates. The correlations between groups was calculated with 
Spearman’s non-parametric tests. To predict the unfavourable outcome of 
ischemic stroke patients based on the biomarker level and the clinical income 
parameters ROC analysis was performed and Youden index was used to 
describe their performance. Statistical significance was set at p≤0.05. 
Statistical analyses were performed using SPSS software, version 23.0 and 
Microsoft excel (2016) was used to calculate Youden index. 
In paper V, to compare the neurofilament concentrations between ALS patients 
and the other groups, a one-way ANOVA with pre-determined contrast tests 
and a 1000 run, bias-corrected accelerated bootstrap was used. The relationship 
between neurofilament concentrations and patient survival was investigated 
with a Spearman’s non-parametric test. Patients were grouped into three 
groups based on a survival of <2 years, 2<10 years and 10< years and analysed 
the differences in biomarker levels between the groups using a one-way 
ANOVA with a polynomial linear, weighted progression test. Statistical 
significance was set at p≤0.05. Statistical analyses were performed using SPSS 
software, version 24. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
To date, most previous studies have used the same commercial ELISA to 
measure NFL in CSF. To confirm the extensive evidence for NFL as a reliable 
biomarker for axonal damage, we developed a new ELISA method and in this 
paper we present its performance for the measurement of CSF-NFL in different 
neurological disorders. 
Two antibodies were produced for this ELISA, NFL-21 and NFL-23. Both 
antibodies showed high affinity binding full length bovine NFL and human 
recombinant NFL, as well as to the core of recombinant NFL in western blot 
and direct ELISA. 
The newly developed ELISA had a range between 5000pg/mL and 39pg/mL 
with a lower limit of quantification (LLOQ) of 78pg/mL and an upper limit of 
quantification (ULOQ) of 10000pg/mL. Its within-plate and inter-plate 
variations were 8% and 13%, respectively. The CSF samples diluted linearly, 
meaning that a sample with a concentration above the ULOQ can be diluted to 
a concentration within the working range and still give a reliable result, and 
the spike recovery was between 80 and 109% concluding that the 
concentration–signal relationship is similar in the calibration curve and the 
samples. The new ELISA uses bovine NFL as standard protein, it did not cross-
react with NFM or NFH and correlated strongly with the commercial one 
(r=0.9984, p<0.001). 
For the entire cohort, we found a weak correlation between CSF-NFL and age 
(r=0.19, p<0.01) as well as that males had slightly increased NFL than females 
(889pg/mL vs 808pg/mL respectively, p<0.05). 
CSF-NFL was significantly higher in both the inflammatory demyelinating 
diseases (IDD) and MCI-AD/AD-dem groups when compared to the other 
neurological diseases (OND) group (p<0.001 for both comparisons) as well as 
when compared to the Parkinson’s disease group (IDD vs PD p<0.05 and MCI-
AD/AD-dem vs PD p<0.01). There were no statistical difference between the 
IDD and MCI-AD/AD-dem groups or between the PD and OND groups. When 
adjusted for age, NFL could differentiate IDD patients from OND patients with 
a sensitivity and specificity of 86% and 83%, respectively (AUC=0.87); MCI-
AD/AD-dem versus OND with a sensitivity and specificity of 94% and 75%, 
respectively (AUC=0.84) and PD was differentiated from OND with a 
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sensitivity and specificity of 97% and 42%, respectively (AUC=0.69) (figure 
5). 
Within the IDD group, CSF-NFL was not significantly different between the 
MS sub-groups (CIS, RRMS, PPMS and SPMS). However, it was significantly 
higher in patients who had a recent relapse (30 days before CSF sampling) than 
in patients with no evidence of recent disease activity (p<0.001). Moreover, 
the CSF-NFL levels correlated with the degree of neurological impairment, 
scored with the Expanded Disability Status Scale (EDSS), at the time of the 
lumbar puncture (r=0.23, p<0.05). Several associations were found between 
different magnetic resonance imaging (MRI) features and CSF-NFL 
concentrations. Finally, CSF-NFL did not correlate with the time between the 
first clinical symptom manifestation and the CSF sampling. 
Figure 5. CSF NfL values (pg/ml) in the different diagnostic groups. a) CSF 
neurofilament light (NfL) values in IDD, MCI-AD/AD-dem, PD, and OND 
groups; p values are from the ANCOVA adjusted for age and sex; *p < 0.05; 
**p < 0.01; ***p < 0.001. b) Diagnostic value of CSF NfL. IDD vs OND 
comparison (age-adjusted AUC = 0.87, 95% CI 0.80–0.95) is reported as the 
solid line. MCI-AD/AD-dem vs OND comparison (age-adjusted AUC=0.84, 
95% CI 0.74–0.95) is reported as the dashed line. PD vs OND comparison 
(age-adjusted AUC = 0.69, 95% CI 0.56–0.81) is reported as the dotted line. 
AD-dem Alzheimer’s disease dementia, IDD inflammatory diseases of the 
central nervous system, MCI-AD mild cognitive impairment due to Alzheimer’s 
disease, OND other neurological diseases, PD Parkinson’s disease. 
Reprinted from Alzheimer's Research & Therapy volume 10, Article number: 
8. © 2018 The Author(s). 
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Within the MCI-AD/AD-dem group, no statistical difference was found 
between the concentrations of CSF-NFL from MCI-AD patients and AD-dem 
patients. Furthermore, no correlation was seen between CSF-NFL and 
cognitive function at baseline, follow-up nor the change over time. The 
cognitive function was scored with the Mini-Mental State Examination 
(MMSE) test. In addition, CSF-NFL concentration did not correlate with 
disease duration.  
Within the PD group, we observed a positive correlation between CSF-NFL 
levels and motor symptoms scored with the Unified Parkinson’s Disease 
Rating Scale, part III (UPDRS III) (r=0.48, p<0.05). However, when adjusting 
for age it became non-significant. No statistical significant correlations were 
found between CSF-NFL and symptom progression, baseline and follow-up 
cognitive function, or disease duration. The symptom progression was scored 
with the Hoehn & Yahr scale (H&Y). 
In this paper, we reported the performance of a new established ELISA to 
analyse NFL in CSF. The assay displayed robust and accurate measurements 
of NFL in CSF with no cross-reactivity with NFM or NFH. There was a strong 
correlation with the previously established commercial ELISA.  
Our observation of increased NFL in the CSF of IDD patients is in line with 
the results from other studies showing that CIS, RRMS,PPMS and SPMS 
patients have higher CSF-NFL than controls (OND) [121, 185] and that the 
diagnostic accuracy of our ELISA is similar to the one reported with the 
commercial ELISA [185]. In our IDD cohort, CSF-NFL concentrations were 
not significantly different between the different sub-groups. A reason for this 
result could be the low number of patients with progressive MS (n = 8). 
However, we found a non-significant increasing trend in CSF-NFL values 
from the isolated syndromes to RRMS, and to the progressive MS patients, 
thus suggesting that axonal damage increases during the disease course. 
Furthermore, we showed that CSF-NFL correlated to several clinical and MRI 
measures of disease severity. 
Similarly, the observation that the MCI-AD/AD-dem had higher CSF-NFL 
than PD or controls (OND) is concordant with other studies [96, 97]. The 
results suggest that measurement of CSF-NFL with the newly developed 
ELISA has a similar diagnostic accuracy compared with the commercially 
available ELISA. Compared to the classical AD biomarkers, NFL lacks in 
pathophysiological specificity. Therefore, it is desirable to use it in 
combination to Aβ42, t-tau, and p-tau in the diagnostic work-up of 
neurodegenerative dementias. 
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The non-significant difference between CSF-NFL concentrations in PD and 
controls (OND) that we observed was also consistent with the results of a 
previous study [186].  
The key findings of this study are: 1) good analytical performance of the new 
ELISA for CSF-NFL, and 2) the confirmation of significantly higher CSF-NFL 
concentrations in IDD and MCI-AD/AD-dem groups when compared to PD or 
controls (OND). 
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4.2 PAPER II 
Neurofilament light is a well-known biomarker for neuronal injury and 
neurodegeneration. However, NFH has been less extensively studied and the 
potential of phosphorylated NFH (pNFH) as a stroke biomarker and for the 
prediction of clinical outcome is unknown. In this study, we aimed to examine 
the temporal pattern of NFL and pNFH concentrations in serum and CSF from 
patients who have been followed over time after acute ischemic stroke. For this 
purpose, we developed a new ELISA to detect pNFH. 
The new pNFH ELISA used two commercial available antibodies (NF-01 and 
NF-05) and a NFH recombinant protein as standard. It had a measurement 
range between 0.077 and 50ng/mL, a limit of detection (LOD) of 0.066ng/mL 
and the inter-plate precision was 8.8%. The samples did not dilute in a linear 
way, hence all samples were analysed neat. When the calibrator was incubated 
together with alkaline phosphatase, the ELISA signals were reduced. 
Therefore, we conclude that our assay is specific for the phosphorylated form 
of NFH. 
The levels of NFL in CSF and serum showed a similar distribution pattern over 
time. The levels increased over time from Day 0-1 reaching the highest value 
on the 3rd week and decreased almost back to normal after 3-5 months after 
stroke. Similarly, serum and CSF pNFH levels increased over time reaching 
their peak at 3 weeks and returning to baseline values after 3-5 months of stroke 
onset (figure 6).  
CSF-NFL and serum-NFL correlated with each other at several time points 
with the best correlation at 3-5 months (r=0.782; p<0.0001). However, serum-
pNFH and CSF-pNFH did not correlate to each other at any time point. A low 
correlation between CSF-NFL and CSF-pNFH was observed on Day 2-3 
(r=0.513; p<0.05). No other correlations were significant between CSF-pNFH 
and CSF-NFL or serum-NFL and serum-pNFH. 
The size (cm2) of the infarcted area was calculated 3-5 months after stroke 
trough neuroimaging techniques such as computed tomography (CT) or 
magnetic resonance imaging (MRI). CSF-NFL and serum-NFL correlated with 
the size of infarct on Day 7-9 (r=0.44; p<0.05 and r=0.91; p<0.0001 
respectively), 3 weeks (r=0.72; p<0.0001 and r=0.81; p<0.001 respectively) 
and 3-5 months (r=0.63; p<0.001 and r=0.69; p<0.001 respectively). CSF-
pNFH and serum-pNFH did not correlate with the infarct volume at any time 
point. 
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The volume (mL) of the infarct was calculated for those patients who received 
an MRI at 3-5 months. CSF-NFL correlated significantly with the volume at 3 
weeks and 3-5 months (r=0.76; p<0.001; r=0.65; p<0.01 respectively), 
whereas serum-NFL only correlated on Day 7-9 (r=0.72; p<0.05). CSF and 
serum pNFH did not correlate with the volume of the infarction at any time 
point. 
The patient’s status was evaluated with the modified Scandinavian Stroke 
Scale index (SSI) at the same time points as when the samples were taken. A 
correlation was found between SSI and CSF-NFL at three weeks (r=0.60; 
p<0.01) and 3-5 months (r=0.43; p<0.05). However, none of the other 
biomarkers correlated with SSI at any time point. SSI was found to correlate 
with the size of infarction on Day 7-9 (r=0.43; p<0.05) and at three weeks 
(r=0.45; p<0.05), but did not correlate with infarction volume at any time point. 
Barthel Index (BI) was used to score the performance in activity of daily living 
3-5 months after stroke. We found that CSF-NFL correlated negatively with 
BI at three weeks (r=-0.72; p<0.0001) and 3-5 months (r=-0.67; p<0.0001), 
whereas serum-NFL and BI correlated negatively on Day 2-3 (r=-0.79; 
p<0.001), Day 7-9 (r=-0.77; p<0.01), three weeks (r=-0.77; p<0.001) and 3-5 
months (r=-0.72; p<0.0001). BI also correlated with patient status (SSI) on Day 
2-3 (r=-0.45; p<0.05), Day 7-9 (r=-0.59; p<0.01), at three weeks (r=-0.59; 
p<0.01) and 3-5 months (r=-0.67; p<0.0001). 
In this paper, we show the progression of CSF and serum NFL and pNFH over 
the course of 3-5 months after stroke, showing that both biomarkers had their 
peaks at 3 weeks after stroke. It has been previously reported that from day 0 
to 3 weeks serum-pNFH progressively increases after stroke, here we 
corroborate that finding as well as show that both pNFH and NFL in serum and 
CSF decrease back to baseline values after 3-5 months of stroke onset, showing 
that axonal breakdown is no longer prevailing. 
NFL showed a better correlation with size than with volume, this could be 
attributed to the lower number of volume determinations consequent to MRI 
contraindication in several patients (eg cardiac pacemaker). 
Outcome measured as BI correlated well with the levels of NFL in serum from 
all time points, except Day 0-1, whereas CSF-NFL levels only correlated at 
three weeks and 3-5 months. The reasons why pNFH from both serum and CSF 
or NFL in CSF at the early time points did not correlate with outcome is 
obscure. However, little is known about how these biomarkers are transported 
from the damaged tissue to serum. Different pathways would probably 
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implicate different kinetics. Also, regarding pNFH, the antibody-antigen 
interaction is dependent on the phosphorylation state of the protein. pNFH 
released from degraded axons in anoxic tissue might also get 
dephosphorylated, at least partly. This could be one reason for the overall lower 
values for pNFH compared with NFL observed in this study. The NFL protein, 
on the contrary, is only lightly phosphorylated and dephosphorylation probably 
would not change the antigen-antibody interaction of the antibodies used in the 
assay system in this study. 
Patient status, periodically evaluated with the SSI, correlated with the size of 
infarction on Day 7-9 and at three weeks. On Day 2-3, Day 7-9, at three weeks 
and after 3-5 months, SSI also correlated with outcome (BI). Interestingly, both 
CSF and serum NFL correlated with outcome and the size of the infarction at 
the same time points as SSI but with better correlation values, suggesting that 
the extension of the damage in the brain is better reflected by the biomarkers 
and that they can predict outcome more precisely than the clinical scoring. 
However, when we intended to calculate at which time point the biomarkers 
Figure 6. Biomarkers evolution over time after acute ischemic stroke. 
Represented as median with inter quartile range, °=outlier, x=extreme value. 
Statistical significance comparing to group control *=p≤0.05; **=p≤0.01; 
***=p≤0.001; ****=p≤0.0001. Statistical significance comparing to Day 0-1 
#=p≤0.05; # #=p≤0,01; # # #=p≤0.001; # # # #=p≤0.0001. 
Reprinted from Neuroscience Letters, Volume 698, 17 April 2019, Pages 58-
63. © 2019 Elsevier B.V. 
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would have a better prediction of outcome, it became evident that our data set 
did not have enough patients classified as “bad outcome” to be able to compute 
receiver operating characteristic (ROC) curves. Therefore, the potential use of 
NFL and pNFH as predictors of outcome could not be evaluated. 
The key finding of this study is that both CSF and serum NFL and pNFH show 
the dynamics of neuronal injury after stroke with the highest levels on week 3 
and a decrease to almost baseline concentrations at 3-5 months after stroke. 
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4.3 PAPER III 
Analytical methods for the measurement of pNFH by ELISA differ largely 
between laboratories [187-191] and promising novel Simoa approaches have 
not yet been compared in a standardised manner. Furthermore, the associations 
of CSF-pNFH with disease progression and survival have not yet been 
consistently reproduced in blood [3, 187, 191]. In view of these challenges, we 
aimed to compare three novel analytical approaches (one ELISA, a homebrew 
Simoa and a commercial Simoa) for the measurement of pNFH concentrations 
by analysing matched pairs of CSF and serum samples of ALS, FTD and 
control subjects. 
All CSF samples were above the analytical sensitivity of each method whereas 
for serum, 97.1% of the samples were over the analytical sensitivity in the 
homebrew Simoa, 100% in the commercial Simoa and 50% in the ELISA. 
Overall, the coefficients of variation (CVs) were lower in CSF than in serum. 
CSF-pNFH concentrations were highly correlated between the different 
methods: homebrew Simoa vs commercial Simoa: r=0.91, p<0.001; homebrew 
Simoa vs ELISA: r=0.99, p<0.001 and commercial Simoa vs ELISA: r=0.94 
p<0.001 (figure 7 A-C). 
Serum-pNFH measurements were also highly correlated between both Simoa 
methodologies (r=0.95, p<0.001). However, correlations between ELISA and 
both Simoa approaches were weak (homebrew Simoa: r=0.55, p<0.001; 
commercial Simoa: r=0.37, p<0.05) (figure 7 D-F).  
CSF and serum sample measurements strongly correlated in both Simoa 
approaches (homebrew Simoa: r=0.62, p<0.001, and commercial Simoa: 
r=0.62, p<0.001) but not in the ELISA (r=0.19, p˃0.05) (figure 7 G-I).  
All three methods showed significantly higher CSF-pNFH concentrations in 
ALS than in FTD and controls (ALS vs FTD p<0.001 and ALS vs controls 
p<0.001 for all assays). Furthermore, if measured with the ELISA method 
CSF-pNFH was higher in FTD vs controls (p<0.05) but not when measured 
with any of the Simoa assays (figure 7 J-L).  
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When analysed with both Simoa methodologies serum-pNFH was 
significantly higher in ALS vs FTD (p<0.01 for both) and in ALS vs controls 
(p<0.001 for both) but not when measured with the ELISA. Though cohorts 
were not sufficiently powered to yield statistical significance, serum-pNfH 
levels were also quantitatively higher in FTD than in control subjects across 
all three approaches (figure 7 M-O). 
In this paper, we report that pNfH concentrations could be sensitively and 
reliably quantified by all three novel analytical approaches in CSF and that the 
Simoa assays also provided reliable and sensitive measurements of pNFH in 
serum.  
In CSF, pNFH concentrations were highly correlated between the three 
analytical assays, an important characteristic for the comparison across centres 
and future multicentre trials. However, the serum pNFH measurements only 
Figure 7. Associations between pNfH measurements across analytical 
approaches in CSF (A–C) and serum (D–F), correlations between CSF and 
serum pNfH measurements within analytical approaches (G–I), pNfH 
concentrations in FTD, ALS and control subjects measured with different 
approaches in CSF (J–L) and serum (M–O). CSF pNfH measurements were 
highly correlated across all three analytical approaches (A–C). Dot colour 
indicates diagnosis (blue: controls, red: FTD, green: ALS). For serum 
measurements, pNfH levels were highly correlated between both Simoa 
approaches, while the correlations between ELISA and both Simoa 
approaches were considerably weaker (E–F). Correlation between paired 
CSF and serum samples was strong for both the homebrew Simoa and the 
commercial Simoa approach, but not significant for the ELISA measurements 
(G–I). In CSF, all three approaches yielded significantly higher pNfH levels in 
ALS than in both FTD and age-matched control subjects (J–L), CSF pNfH 
levels of FTD subjects were significantly higher than those of controls if 
measured by ELISA (L) (p-values Bonferroni-corrected for multiple 
comparisons, *** p < .001, ** p < .01, * p < .05, ns: not significant). In serum, 
significantly higher pNfH levels in ALS than in FTD and control subjects were 
only found by the Simoa approaches (M–O). Central horizontal lines indicate 
median values, boxes illustrate the ranges between lower and upper quartiles, 
and error bars represent the full ranges of data. Please note the logarithmic 
scale of the x- and y-axis. 
Reprinted with permission from Clinical Chemistry and Laboratory Medicine 
(CCLM), 20190015, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 
https://doi.org/10.1515/cclm-2019-0015. ©2019 Walter de Gruyter GmbH, 
Berlin/Boston. 
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showed a strong correlation between the two Simoa assays. A weaker 
correlation between the ELISA and both Simoa methods might be due to the 
lower analytical sensitivity and the high number of serum samples that fell 
outside the analytical range of the ELISA. 
Serum-pNFH measurements correlated strongly with CSF measurements, 
when measured by either of the two Simoa approaches but not when analysed 
with ELISA. The correlation between CSF and serum pNFH levels measured 
by ELISA might result from its limitations in sensitivity, affecting the serum 
measurements. 
All three pNFH assays seemed suited to unveil relevant findings in the 
neurodegenerative disease cohorts. All three methods distinguished ALS 
subjects from control and FTD subjects by CSF-pNFH concentrations, with 
the Simoa assays also detecting this distinction in serum. These findings 
support the validity of the assays and extend previous findings of increased 
pNFH levels in ALS by demonstrating that this increase is consistent and 
reliable across different analytical approaches. 
The key finding of this paper is that CSF-pNFH concentrations are correlated 
between the different assays and consistently increased in ALS patients 
compared to controls, independently of which assay was used. 
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4.4 PAPER IV 
We have previously reported how NFL concentrations in CSF and serum 
progress after acute ischemic stroke (paper II). However, we could not 
determine its prognostic capabilities due to the characteristics of our cohort. In 
this paper, we aimed to investigate several biomarkers (NFL, tau, GFAp, NSE 
and S100B) in blood to further understand the progression of nervous tissue 
damage and their relationship to outcome after endovascular treatment of acute 
ischemic stroke, as well as to determine their possible use as prognostic 
biomarkers and their relationship with clinical biomarkers. 
Blood samples were taken before endovascular treatment (pre) and 2h, 24h, 
48h, 72h and 3 months after treatment. Each biomarker progressed slightly 
differently over time. Tau was lowest before endovascular treatment, 
progressively increased until 72h after treatment and decreased back to 
baseline at 3 months. NFL had a slower increase over time when compared to 
tau, with its lowest concentration found at pre-embolectomy to slow and 
constantly increase until 3 months after treatment. GFAp and S100B both 
reached their peak at 48h and decreased back to baseline values after 3 months, 
whereas NSE remained constant over time (figure 8). 
The volume of the infarcted area was measured on day 1 using a CT and on 
day 3 using an MRI. Both volumes correlated to all blood biomarkers at least 
at two time points. However, GFAp was the only marker that already at 2h 
correlated significantly with volumes day 1 and 3 (r=0.51, p<0.0001 and 
r=0.47, p<0.0001, respectively). 
Clinical stroke severity was estimated using the National Institute of Health 
Stroke Scale (NIHSS) at admission and at 24h after endovascular treatment. 
Tau, NFL and GFAp correlated to admission NIHSS at least at one time point 
while NSE and S100B did not correlate at any. All blood biomarkers correlated 
to NIHSS at 24h at least at one time point. 
The Alberta Stroke Program Early CT score (ASPECTS) was used to assess 
stroke severity using available CT data. On day 3, all blood biomarkers 
correlated with ASPECTS, at least at one time point, whereas only NFL, tau 
and GFAp correlated with ASPECTS at admission. 
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The degree of recanalization after the embolectomy, evaluated by angiography, 
was defined according to the modified thrombolysis in cerebral ischemia 
(mTICI). Only GFAp and NSE correlated with mTICI (two time points and 
one time point respectively). Tau, NFL and S100B did not correlate to mTICI 
at any time point. 
The modified ranking scale (mRS) was used to assess the degree of disability 
or dependence in the daily activities 3 months after stroke. All blood 
biomarkers correlated with mRS at least at one time point, with both tau and 
GFAp already correlating to mRS at 2h after stroke. All clinical biomarkers 
Figure 8. Biomarker progression. Concentration of biomarkers per time 
point (pre, 2h, 24h, 48h, 72h and 3 months). A) TAU pg/ml. B) NFL pg/ml. C) 
GFAP pg/ml. D) NSE ng/ml. E) S100B µg/ml. °=outlier, x=extreme value. 
Statistical significance comparing to pre ✱=p≤0.05; ✱✱=p≤0.01; 
✱✱✱=p≤0.001; ✱✱✱✱=p≤0.0001. (S100B: statistical significance 
comparing to 3 months #=p≤0.05; # #=p≤0.01; # # #=p≤0.001; # # # 
#=p≤0.0001). 
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(admission NIHSS, NIHSS at 24h, ASPECTS at 72h, infarct volume day 1, 
infarct volume day 3 and mTICI) at the exception of admission ASPECTS, 
also correlated with the severity of outcome 3 months after stroke. 
The best time to predict poor outcome, defined as mRS≥3, was for tau at 2h or 
48h (AUC=0.76 both) and for GFAp at 72h (AUC=0.81). NFL had the highest 
predictive capacity at 3 months (AUC=0.88). However, since 3 months is the 
time as the outcome was evaluated, we therefore assigned 72h (AUC=0.79) as 
the best time for NFL to predict for outcome. Both NSE and S100B predicted 
best at 24h (AUC=0.67 and 0.70 respectively). Most clinical biomarkers had a 
good prediction of poor outcome. Admission NIHSS (AUC=0.65), NIHSS at 
24h (AUC=0.86), admission ASPECTS (AUC=0.60), ASPECTS at 3 days 
(AUC=0.77), infarct volume on day 1 (AUC=0.73), infarct volume on day 3 
(AUC=0.78) and mTICI (AUC=0.61).  
To determine if the prediction for poor outcome could be improved, we 
combined clinical parameters and blood biomarkers. The combination of the 
clinically accessible parameter NIHSS at 24h, and biomarkers with AUCs>0.7 
at 48h, i.e., tau, NFL and GFAp were chosen. All combinations had similar 
predictive capacity (AUC=0.891, 0.894 and 0.890, respectively) and improved 
the prediction of poor outcome when compared to the prediction with a single 
factor. 
In this paper, we reported the different progression patterns of tau, NFL, GFAp, 
NSE and S100B in blood after acute ischemic stroke and their potential use 
together with clinical biomarkers to predict for poor outcome after 3 months. 
The different kinetics of each blood biomarker possibly reflect the different 
cellular and subcellular locations, considering that GFAp and S100B are 
located in astroglial cells and tau, NFL and NSE are located in neurons. 
Furthermore, tau is more prevalent in thin unmyelinated axons whereas NFL 
is mainly expressed in large myelinated axons. However, S100B and NSE are 
also present outside the nervous system, e.g., in adipose and neuroendocrine 
tissue, as well as in blood cells.  
Tau, NFL and GFAp were moderately to highly correlated with infarct volume, 
NIHSS at 24h and mRS at 3 months. Regarding NSE and S100B, however, 
correlations were very low and mainly insignificant. In the scientific 
community, there is controversy regarding the usefulness of NSE and S100B 
as biomarkers of CNS injury since there are opposite results in different studies 
[192-194]. Our results suggest that tau, NFL and GFAp in blood reflect the 
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extent of nervous tissue damage after ischemic stroke, whereas NSE and 
S100B are of little value.  
Regarding the prediction of outcome, the best performing biomarker was NFL 
at 72h followed by GFAp at 72h and tau at 2 hours. NIHSS at 24h predicted 
outcome slightly better than the blood biomarkers, whereas ASPECTS at day 
3 and infarct volume at both days 1 and 3 had similar prediction levels. 
Admission NIHSS and ASPECTS, as well as mTICI, had a poor prediction of 
outcome compared with the biomarkers. The combination of NIHSS at 24h 
and NFL, tau or GFAp at 48h improved the performance in predicting poor 
outcome compared with a single biomarker, suggesting that these blood 
biomarkers could be used as complementary tests to confirm the severity of 
the stroke. 
The key findings of this study are: 1) the different blood biomarkers show 
different kinetics over time after ischemic stroke, and 2) their performance in 
predicting for poor outcome, also in combination with clinical parameters such 
as NIHSS at 24h, was high. 
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4.5 PAPER V 
ALS is a fatal neurodegenerative MND characterized by progressive loss of 
upper and lower motor neurons. CSF concentrations of NFL and pNFH have 
been found to be increased in ALS [77, 94, 115]. In this study, we aimed to 
test the hypothesis that CSF NFL and pNFH can differentiate ALS patients 
from patients with ALS-like symptoms who eventually received other 
diagnoses. In addition, we examined if the biomarkers were correlated with 
disease survival and if the mutation type in genetic cases had an influence on 
the biomarker levels. 
In the whole cohort, CSF-NFL and CSF-pNFH were significantly correlated 
to each other (r=0.817, p<0.0001). 
ALS patients had higher CSF NFL and pNFH compared with referral patients 
with myo-/neuro-/myelopathies (p<0.001 for both NFL and pNFH), patients 
with other neurological conditions (NFL: p<0.01, pNFH: p<0.001)), patients 
with other neurodegenerative diseases (p<0.001 for both) and healthy controls 
(p<0.001 for both) (figure 9). 
Neither NFL nor pNFH was significantly different between patients with 
bulbar or spinal onset.  
Both NFL and pNFH correlated with survival time from symptom onset, 
however; NFL had a stronger correlation than pNFH (NFL: r=-0.307, 
p<0.0001; pNFH: r=-0.158, p<0.05). 
By grouping the patients in intervals of short (<2 years), intermediate (2-10 
years) and long (>10 years) survival time, we observed that for NFL there was 
a significant difference (p<0.001) between the 3 groups in a linear negative 
trend, where patients with longer survival had lower concentration of NFL. 
The same trend, but not significant, was seen for the pNFH concentrations. 
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Within our ALS group, there were 26 C9orf72 hexanucleotide repeat 
expansion (HRE) carriers, 24 superoxide dismutase 1 (SOD1) mutation 
carriers and 4 vesicle-associated membrane protein B (VAPB) mutation 
carriers. However, the great majority (n=192) did not have a detectable 
mutation. Neither NFL nor pNFH differed between the different mutation 
carrier groups or between the carrier and non-carrier groups. However, the 
C9orf72 HRE patients had noticeably higher NFL concentrations (median; 
IQR: 5419; 4258-6621pg/mL) compared with SOD1 mutation carriers 
(median; IQR: 3248; 2333-4472pg/mL) and non-carriers (median; IQR: 3740; 
2260-5802pg/mL). 
In this paper, we showed that the ALS group had higher NFL and pNFH 
concentrations in CSF compared with the healthy controls, referral patients 
with myo-/neuropathies and patients with other non-degenerative neurological 
conditions. Due to the different inclusion criteria for the diagnosis of ALS and 
differences in the terminology used across the different publications, it is 
complicated to make proper comparisons between studies. However, our 
results are in line with the general observation from other studies to show that 
both NFL and pNFH are elevated in the CSF of ALS patients [111].  
Our results support previous findings that CSF neurofilament levels cannot 
differentiate ALS patients according the site of onset (spinal or bulbar) [195], 
suggesting that the extent of ongoing neuronal degeneration is similar in both 
types of onset, despite the poorer prognosis in bulbar onset patients. In some 
way, the worse prognosis in bulbar onset cases could be in part due to the 
earlier dysphagia, which in turn would affect the nutritional intake and by 
extension influence the course of the disease due to the increased metabolic 
demand present in ALS [196-198]. 
We found that ALS patients with lower concentrations of the biomarkers had 
longer survival times; we therefore assume that patients with lower biomarker 
concentrations had less intense neurodegeneration.  
Figure 9. Biomarker concentrations in the different diagnostic groups. A) 
CSF-NFL (pg/mL) B) CSF-pNFH (pg/mL). Center of box defines median 
values, upper and lower box limits defines first (Q1) and third (Q3) quartiles. 
Whiskers defines +/-1.5 times interquartiles range (IQR). Diamonds indicate 
cases outside 1.5 times IQR. Filled circles indicate cases outside 3 times IQR. 
When comparing all groups, the overall One-Way ANOVA was significant at 
p<0.0001. Statistical significance comparing other groups to the ALS group is 
denominated with asterisk *=p≤0.05; **=p≤0.01; ***=p≤0.001. 
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It has been previously reported that ALS patients carrying C9orf72 HREs have 
higher pNFH levels compared to non-mutation carriers and that SOD1 
mutation carriers have lower NFL levels when compared with non-mutation 
carriers [108, 189]. Our results corroborate these results. In addition, we show 
that NFL is also higher in C9orf72 HRE carriers compared with non-mutation 
carriers, and that pNFH is higher in SOD1 mutation carriers when compared 
to non-mutation carriers, which contrasts NFL. The transcriptome of induced 
pluripotent stem cells (iPSC)-derived motor neurons carrying C9orf72 HREs 
is different from the one of iPSC-derived motor neurons with SOD1 mutations 
[199], and perhaps the differences we observed in the biomarker 
concentrations across the different mutation carriers could be a consequence 
of the pathophysiology caused by such mutation. 
The key findings of this study are: 1) the increased concentrations of both NFL 
and pNFH in the CSF of ALS patients as compared to ALS-mimics and healthy 
controls, 2) the correlation of both biomarkers with survival and 3) the different 
biomarker profile in the different mutation carrier groups. 
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5 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
The work included in this thesis includes method development and clinical 
studies to qualify the potential use of neurofilaments as biomarkers of neuronal 
damage in different situations. 
The newly developed ELISA to measure NFL in CSF showed a good analytical 
performance, correlated with the established commercial assay, and showed 
similar diagnostic accuracy in distinguishing IDD patients from controls. 
Therefore, we conclude that our assay represents a valid alternative method for 
the measurement of NFL in CSF and that CSF-NFL is a reliable biomarker of 
the severity of the axonal damage processes occurring in different neurological 
diseases. 
The newly developed ELISA for the measurement of pNFH was specific for 
the phosphorylation form of NFH. On the one hand, it performed well for the 
measurement of pNFH in CSF. On the other hand, its analytical sensitivity was 
not high enough to be used for serum analyses. Therefore, one of the Simoa 
assays would be preferable for the analysis of pNFH in serum. The increased 
concentration of pNFH in several neurodegenerative diseases and the 
correlation between CSF and serum values suggest that pNFH, like NFL, could 
become a promising blood biomarker of neuronal damage, which is valid 
across different analytical platforms. Therefore, more studies are needed to 
further prove this point, as well as to further qualify the diagnostic 
differentiation capabilities of the neurofilaments. These future studies should 
be performed, preferably, including other established biomarkers such as tau 
GFAp and/or clinical parameters which could be used together with the NFs, 
or if time is of importance, perhaps instead of them, as for tau at 2h had a 
reasonable prediction performance compared to NFL at 72h. Furthermore, the 
combination of different biomarkers improved the prediction of outcome in 
stroke, so it may be possible that it can also improve the diagnostic capabilities 
of one single biomarker.  
NFL and pNFH in either blood or CSF are biomarkers reflecting the temporal 
dynamics of post-ischemic degeneration of axons. Their use in the early setting 
after endovascular treatment of stroke could lead to a simplified and 
standardized way to estimate the nervous tissue damage and possibly 
complement the clinical judgment in foreseeing the need of rehabilitation 
measures, especially if combined with other biomarkers such as NIHSS at 24h. 
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However, for a better understanding of the full potential of these markers, 
further studies in different subsets of stroke are needed.  
The observed correlations of CSF-NFL with serum-NFL and CSF-pNFH with 
serum-pNFH suggest the possibility of the use of future blood-based tests in 
the clinic due to the easier accessibility to blood samples. 
An interesting point to study in the future would be the relationship between 
pNFH and NFH. Since the phosphorylation-dephosphorylation dynamics 
could be altered in different ways in different neurodegenerative diseases 
depending on their neurodegenerative pathway. Similarly, the study of INA, 
which is CNS-specific, could complement the information given by the other 
neurofilaments and allow for making stronger statements regarding the CNS-
specificity of a blood neurofilament concentration change. 
Also further studies in the protein structure are needed since it has been 
postulated that NFL in CSF could be degraded and/or aggregated [129]. This 
would give insight into the dynamics of neurofilament degradation that could 
also vary in different neurodegenerative diseases, similarly to the 
phosphorylation status of NFH. 
In conclusion, the work presented in this thesis shows that both NFL and pNFH 
proved to be sensitive and reliable biomarkers of neuronal damage, which 
further qualifies their use as disease intensity markers and shows their great 
potential as laboratory tests in the diagnostics of neurodegenerative diseases.  
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